---
title: "LGVN.US (LGVN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LGVN.US/news.md"
symbol: "LGVN.US"
name: "LGVN.US"
parent: "https://longbridge.com/en/quote/LGVN.US.md"
datetime: "2026-05-20T12:03:19.755Z"
locales:
  - [en](https://longbridge.com/en/quote/LGVN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LGVN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LGVN.US/news.md)
---

# LGVN.US (LGVN.US) — Related News

### [Longeveron Q1 2026 Earnings Call: Complete Transcript](https://longbridge.com/en/news/286319416.md)
*2026-05-13T21:09:05.000Z*
> Longeveron (NASDAQ:LGVN) reported Q1 2026 revenues of $0.4 million, unchanged from the previous year. Clinical trial rev

### [Longeveron | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 398 K](https://longbridge.com/en/news/286311858.md)
*2026-05-13T20:22:58.000Z*
### [Longeveron | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 398 K](https://longbridge.com/en/news/286309548.md)
*2026-05-13T20:08:12.000Z*
### [12 Health Care Stocks Moving In Monday's Pre-Market Session](https://longbridge.com/en/news/285942175.md)
*2026-05-11T12:06:13.000Z*
> In Monday's pre-market session, several health care stocks saw significant movement. Alpha Tau Medical (DRTS) rose 13.5%

### [Longeveron Holds Constructive FDA Meeting; ELPIS II Topline Data Expected August 2026](https://longbridge.com/en/news/285908817.md)
*2026-05-11T08:50:20.000Z*
> Longeveron Inc. (LGVN) held a constructive meeting with the FDA regarding its Phase 2b ELPIS II trial for laromestrocel 

### [Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS) | LGVN Stock News](https://longbridge.com/en/news/285949144.md)
*2026-05-11T05:10:34.000Z*
> Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem